Zinc and Vitamin C: study protocols
41 study groups took Zinc together with Vitamin C. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Zinc
41 study groups in 33 studies say how much Zinc participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 10 mg to 25 mg, 32% of 41 study groups.
| Daily dose | Study groups |
|---|---|
| 2.5 mg or less | 1 |
| 2.5 mg to 5 mg | 7 |
| 5 mg to 10 mg | 6 |
| 10 mg to 25 mg | 13 |
| 25 mg to 50 mg | 4 |
| 50 mg to 100 mg | 10 |
Dose per serving from research: Vitamin C
37 study groups in 30 studies say how much Vitamin C participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 30% of 37 study groups.
| Daily dose | Study groups |
|---|---|
| 25 mg or less | 2 |
| 25 mg to 50 mg | 9 |
| 50 mg to 100 mg | 5 |
| 100 mg to 250 mg | 9 |
| 250 mg to 500 mg | 11 |
| over 500 mg | 1 |
Commonly used together
38 of 41 study groups took Zinc and Vitamin C with something else. Shown: what 3 or more different studies gave. The 10 most common of 16.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin E | 30 |
| Vitamin A | 18 |
| Copper | 17 |
| Iron | 16 |
| Beta-Carotene | 15 |
| Selenium | 14 |
| Vitamin D | 10 |
| Folic Acid | 9 |
| Iodine | 8 |
| Vitamin B12 | 7 |
41 study groups
| Study | ||||
|---|---|---|---|---|
| Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial 2021 · Zinc & vitamin C · Men aged 21–60 living in a high-exposure migrant-worker dormitory in Singapore, without known COVID-19 at enrollment | 80 mg | 500 mg | 6 weeks | 634 |
| Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis 2016 · combination of antioxidants and zinc · Adults aged 55 years and older with age-related macular degeneration; eyes with advanced disease at baseline and participants with no AMD in both eyes were excluded | 80 mg | 500 mg | 2409 days | — |
| Impact of iron fortification on anaemia and iron deficiency among pre-school children living in Rural Ghana 2021 · non-iron MNP group · Children aged 6–35 months living in rural Ghana; children with severe anaemia, severe malnutrition, recent iron supplementation, or chronic disease were excluded. | 5 mg | 30 mg | 150 days | 991 |
| Impact of iron fortification on anaemia and iron deficiency among pre-school children living in Rural Ghana 2021 · iron-MNP group · Children aged 6–35 months living in rural Ghana; children with severe anaemia, severe malnutrition, recent iron supplementation, or chronic disease were excluded. | 5 mg | 30 mg | 150 days | 967 |
| Megadose vitamins in bladder cancer: a double-blind clinical trial 1994 · megadose vitamins arm · Patients with biopsy-confirmed transitional cell carcinoma of the bladder receiving BCG immunotherapy | 90 mg | 2 g | — | 35 |
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 80 mg | 500 mg | 8 years | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 30 mg | 100 mg | — | — |
| Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13 2004 · antioxidants plus zinc · Adults aged 55–81 years with AMD categories 2–4 and AREDS ocular eligibility | 80 mg | 500 mg | 339 weeks | — |
| The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals 2004 · antioxidant supplement group · French women aged 35–60 and men aged 45–60 in the general population | 20 mg | 120 mg | 2739 days | — |
| Antioxidant status and risk of cancer in the SU.VI.MAX study: is the effect of supplementation dependent on baseline levels? 2005 · daily antioxidant supplementation · French adults: women aged 35–60 years and men aged 45–60 years | 20 mg | 120 mg | 2739 days | — |